Navigation Links
Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate

PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Arrowhead Research Corporation (NASDAQ: ARWR) announced the publication by its majority-owned subsidiary Calando Pharmaceuticals, Inc. of a study demonstrating the anti-proliferative effect of the siRNA sequence selected as the therapeutic component of its lead anti-cancer compound, CALAA-01.

The paper, entitled "Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo", was published in Clinical Cancer Research, a journal published by the American Association of Cancer Research (AACR). This paper describes how Calando's proprietary siRNA duplex demonstrated silencing of the target gene, RRM2, and reduced cell proliferation across multiple species and cancer types, both in cell culture and in whole animals. These findings confirm that this duplex is a promising candidate for therapeutic development.

"The paper reports some of the great progress being made at Calando," said R. Bruce Stewart, Chairman and CEO of Arrowhead. "We believe that siRNA will be one of the corner stones of cancer treatment in the future".

"These studies demonstrate the potential for this siRNA duplex to have a strong anti-tumor effect," said John Petrovich, Calando's Chief Executive Officer. He further added that Calando has filed for patent protection on several siRNA duplexes against the RRM2 target and has licensed patents from Alnylam Pharmaceuticals to enable it to develop and commercialize an RNAi therapeutic against this target.

Further information about Calando can be found at www.calandopharma.com.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of ma
'"/>




Page: 1 2 3

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
3. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
6. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... , April 26 e-MDs, an industry leader ... and practice management (PM) solutions, announced they have been selected ... Alaska EHR Alliance (AEHRA).   e-MDs was identified through ... Alaska healthcare providers looking to incorporate an EHR in ...
... 26 Sirion Therapeutics, Inc., a privately held ophthalmic ... is now commercially available.  Zirgan™, which was approved by the ... is a topical ophthalmic antiviral indicated for the treatment of ... , , ...
Cached Medicine Technology:Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 2Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 3Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 4Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3
(Date:7/10/2014)... as tempting as full-fat equivalents could be heading ... how proteins can replace fats without affecting foodstuffs, ... Engineering and Physical Sciences Research Council (EPSRC), a ... Edinburgh has produced modified proteins that easily break ... behaviour of fats during food manufacture. The proteins ...
(Date:7/9/2014)... 2014 -- The World Health Organization recommends that youth ... to vigorous physical activity (MVPA) each day. Studies ... during school hours. Therefore, it stands to reason ... MVPA. In a new study scheduled for publication ... that time spent outdoors after school was positively associated ...
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2
... triples risk of disease, study funds , , WEDNESDAY, ... to be predictors of esophageal cancer have been identified ... M. D. Anderson Cancer Center team pinpointed 11 single-nucleotide ... with esophageal cancer. , Each of these unfavorable genotypes ...
... Marketing Messages for Advair,and Xolair, According to a ... Nov. 5 Decision Resources one of the,world,s ... and,healthcare issues, finds that physicians and patients respond ... to use.,Physicians indicate that brands conveying messages of ...
... Stay Balanced Through the ... ... and New York Times best-selling author Ellie Krieger, of Food Network,fame, ... health. Yo-Plus contains live and active probiotic cultures,specifically designed for digestive ...
... PITTSBURGH, Nov. 5 CardiacAssist, Inc. announced that,it reached a ... System,performing at least one TandemHeart case during the third quarter ... highest year on,year growth in case activity with a leap ... 70 % and 497 %. Through nine months of 2008,CardiacAssist ...
... for passengers taking 7- to ... 9-hour flights, ... Minerva Cardioangiologica reveals Pycnogenol(R), pine bark,extract from the French maritime pine tree, ... a brain CT scan and a,scoring system, showed Pycnogenol(R) lowered symptoms of ...
... companies is often dependent on their ability to do deals ... A Comprehensive Assessment of Valuation in the Pharmaceutical Sector, the ... aspects of deal-making, including valuations and royalty rate calculations. ... ...
Cached Medicine News:Health News:Researchers ID Genetic Markers for Esophageal Cancer 2Health News:Physicians Rank Schering-Plough's Marketing Messages for Asmanex as the Most Appealing in the Asthma Drug Market 2Health News:Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health 2Health News:Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health 3Health News:CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results 2Health News:Study Shows Pine Bark Reduces Jetlag 2Health News:Study Shows Pine Bark Reduces Jetlag 3Health News:Study Shows Pine Bark Reduces Jetlag 4Health News:Determining Valuations in Challenging Times 2Health News:Determining Valuations in Challenging Times 3Health News:Determining Valuations in Challenging Times 4
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...
Medicine Products: